Selective axillary dissection after axillary reverse mapping to prevent breast-cancer-related lymphoedema.
Identifieur interne : 001892 ( PubMed/Checkpoint ); précédent : 001891; suivant : 001893Selective axillary dissection after axillary reverse mapping to prevent breast-cancer-related lymphoedema.
Auteurs : M. Gennaro [Italie] ; M. Maccauro ; C. Sigari ; P. Casalini ; L. Bedodi ; A R Conti ; A. Caraceni ; E. BombardieriSource :
- European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [ 1532-2157 ] ; 2013.
Descripteurs français
- KwdFr :
- Aisselle (), Femelle, Humains, Lymphadénectomie (), Lymphoedème (), Lymphoedème (étiologie), Lymphoscintigraphie, Métastase lymphatique, Noeuds lymphatiques (), Noeuds lymphatiques (imagerie diagnostique), Radiopharmaceutiques, Technétium, Traitements préservant les organes, Tumeurs du sein (), Tumeurs du sein (anatomopathologie).
- MESH :
- anatomopathologie : Tumeurs du sein.
- imagerie diagnostique : Noeuds lymphatiques.
- étiologie : Lymphoedème.
- Aisselle, Femelle, Humains, Lymphadénectomie, Lymphoedème, Lymphoscintigraphie, Métastase lymphatique, Noeuds lymphatiques, Radiopharmaceutiques, Technétium, Traitements préservant les organes, Tumeurs du sein.
English descriptors
- KwdEn :
- Axilla (surgery), Breast Neoplasms (complications), Breast Neoplasms (pathology), Female, Humans, Lymph Node Excision (methods), Lymph Nodes (diagnostic imaging), Lymph Nodes (surgery), Lymphatic Metastasis, Lymphedema (etiology), Lymphedema (prevention & control), Lymphoscintigraphy, Organ Sparing Treatments, Radiopharmaceuticals, Technetium.
- MESH :
- chemical : Radiopharmaceuticals, Technetium.
- complications : Breast Neoplasms.
- diagnostic imaging : Lymph Nodes.
- etiology : Lymphedema.
- methods : Lymph Node Excision.
- pathology : Breast Neoplasms.
- prevention & control : Lymphedema.
- surgery : Axilla, Lymph Nodes.
- Female, Humans, Lymphatic Metastasis, Lymphoscintigraphy, Organ Sparing Treatments.
Abstract
It has recently been reported that, using axillary reverse mapping (ARM), the lymphatics from the arm can be spared to reduce the incidence of breast-cancer-related lymphoedema (BCRL). The aim of this study was to assess the feasibility of selective axillary dissection (SAD) after using ARM and partially preserving arm drainage, and to assess the occurrence of BCRL.
DOI: 10.1016/j.ejso.2013.09.022
PubMed: 24113621
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:24113621Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Selective axillary dissection after axillary reverse mapping to prevent breast-cancer-related lymphoedema.</title><author><name sortKey="Gennaro, M" sort="Gennaro, M" uniqKey="Gennaro M" first="M" last="Gennaro">M. Gennaro</name><affiliation wicri:level="1"><nlm:affiliation>Breast Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy. Electronic address: massimiliano.gennaro@istitutotumori.mi.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Breast Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Maccauro, M" sort="Maccauro, M" uniqKey="Maccauro M" first="M" last="Maccauro">M. Maccauro</name></author><author><name sortKey="Sigari, C" sort="Sigari, C" uniqKey="Sigari C" first="C" last="Sigari">C. Sigari</name></author><author><name sortKey="Casalini, P" sort="Casalini, P" uniqKey="Casalini P" first="P" last="Casalini">P. Casalini</name></author><author><name sortKey="Bedodi, L" sort="Bedodi, L" uniqKey="Bedodi L" first="L" last="Bedodi">L. Bedodi</name></author><author><name sortKey="Conti, A R" sort="Conti, A R" uniqKey="Conti A" first="A R" last="Conti">A R Conti</name></author><author><name sortKey="Caraceni, A" sort="Caraceni, A" uniqKey="Caraceni A" first="A" last="Caraceni">A. Caraceni</name></author><author><name sortKey="Bombardieri, E" sort="Bombardieri, E" uniqKey="Bombardieri E" first="E" last="Bombardieri">E. Bombardieri</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:24113621</idno><idno type="pmid">24113621</idno><idno type="doi">10.1016/j.ejso.2013.09.022</idno><idno type="wicri:Area/PubMed/Corpus">001893</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001893</idno><idno type="wicri:Area/PubMed/Curation">001893</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001893</idno><idno type="wicri:Area/PubMed/Checkpoint">001893</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001893</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Selective axillary dissection after axillary reverse mapping to prevent breast-cancer-related lymphoedema.</title><author><name sortKey="Gennaro, M" sort="Gennaro, M" uniqKey="Gennaro M" first="M" last="Gennaro">M. Gennaro</name><affiliation wicri:level="1"><nlm:affiliation>Breast Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy. Electronic address: massimiliano.gennaro@istitutotumori.mi.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Breast Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Maccauro, M" sort="Maccauro, M" uniqKey="Maccauro M" first="M" last="Maccauro">M. Maccauro</name></author><author><name sortKey="Sigari, C" sort="Sigari, C" uniqKey="Sigari C" first="C" last="Sigari">C. Sigari</name></author><author><name sortKey="Casalini, P" sort="Casalini, P" uniqKey="Casalini P" first="P" last="Casalini">P. Casalini</name></author><author><name sortKey="Bedodi, L" sort="Bedodi, L" uniqKey="Bedodi L" first="L" last="Bedodi">L. Bedodi</name></author><author><name sortKey="Conti, A R" sort="Conti, A R" uniqKey="Conti A" first="A R" last="Conti">A R Conti</name></author><author><name sortKey="Caraceni, A" sort="Caraceni, A" uniqKey="Caraceni A" first="A" last="Caraceni">A. Caraceni</name></author><author><name sortKey="Bombardieri, E" sort="Bombardieri, E" uniqKey="Bombardieri E" first="E" last="Bombardieri">E. Bombardieri</name></author></analytic><series><title level="j">European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology</title><idno type="eISSN">1532-2157</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Axilla (surgery)</term><term>Breast Neoplasms (complications)</term><term>Breast Neoplasms (pathology)</term><term>Female</term><term>Humans</term><term>Lymph Node Excision (methods)</term><term>Lymph Nodes (diagnostic imaging)</term><term>Lymph Nodes (surgery)</term><term>Lymphatic Metastasis</term><term>Lymphedema (etiology)</term><term>Lymphedema (prevention & control)</term><term>Lymphoscintigraphy</term><term>Organ Sparing Treatments</term><term>Radiopharmaceuticals</term><term>Technetium</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Aisselle ()</term><term>Femelle</term><term>Humains</term><term>Lymphadénectomie ()</term><term>Lymphoedème ()</term><term>Lymphoedème (étiologie)</term><term>Lymphoscintigraphie</term><term>Métastase lymphatique</term><term>Noeuds lymphatiques ()</term><term>Noeuds lymphatiques (imagerie diagnostique)</term><term>Radiopharmaceutiques</term><term>Technétium</term><term>Traitements préservant les organes</term><term>Tumeurs du sein ()</term><term>Tumeurs du sein (anatomopathologie)</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Radiopharmaceuticals</term><term>Technetium</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Lymph Nodes</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Noeuds lymphatiques</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Lymph Node Excision</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Axilla</term><term>Lymph Nodes</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Lymphoedème</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Lymphatic Metastasis</term><term>Lymphoscintigraphy</term><term>Organ Sparing Treatments</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Aisselle</term><term>Femelle</term><term>Humains</term><term>Lymphadénectomie</term><term>Lymphoedème</term><term>Lymphoscintigraphie</term><term>Métastase lymphatique</term><term>Noeuds lymphatiques</term><term>Radiopharmaceutiques</term><term>Technétium</term><term>Traitements préservant les organes</term><term>Tumeurs du sein</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">It has recently been reported that, using axillary reverse mapping (ARM), the lymphatics from the arm can be spared to reduce the incidence of breast-cancer-related lymphoedema (BCRL). The aim of this study was to assess the feasibility of selective axillary dissection (SAD) after using ARM and partially preserving arm drainage, and to assess the occurrence of BCRL.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24113621</PMID><DateCreated><Year>2013</Year><Month>11</Month><Day>25</Day></DateCreated><DateCompleted><Year>2014</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2157</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>12</Issue><PubDate><Year>2013</Year><Month>Dec</Month></PubDate></JournalIssue><Title>European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology</Title><ISOAbbreviation>Eur J Surg Oncol</ISOAbbreviation></Journal><ArticleTitle>Selective axillary dissection after axillary reverse mapping to prevent breast-cancer-related lymphoedema.</ArticleTitle><Pagination><MedlinePgn>1341-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejso.2013.09.022</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0748-7983(13)00836-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">It has recently been reported that, using axillary reverse mapping (ARM), the lymphatics from the arm can be spared to reduce the incidence of breast-cancer-related lymphoedema (BCRL). The aim of this study was to assess the feasibility of selective axillary dissection (SAD) after using ARM and partially preserving arm drainage, and to assess the occurrence of BCRL.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using a radioisotope and lymphoscintigraphy, ARM was performed in 60 patients scheduled for SAD, who were subsequently divided for the purpose of comparing the BCRL rates into: group A, comprising 45 patients who successfully underwent SAD with a residual lymphatic hot spot; and group B with 15 whose hot nodes were removed as is normally the case during complete axillary lymph node dissection (ALND).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">SAD was feasible in 75% of the 60 patients. SAD was completed successfully in 19 of the first 30 patients, and in 26 of the second 30 patients (p = 0.072). The median follow-up was 16 months (6-36), during which 9 patients developed a BCRL, 4 in group A (9%) and 5 in group B (33%); p = 0.035. None of the patients had nodal relapses during the follow-up.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Using a radioisotope enables an effective and safe SAD in a large proportion of patients. There was evidence of a trend to suggest a learning curve. The rate of BCRL after SAD was less than one third of the rate recorded after ALND, a result that should encourage the development of the former technique.</AbstractText><CopyrightInformation>Copyright © 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gennaro</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Breast Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy. Electronic address: massimiliano.gennaro@istitutotumori.mi.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maccauro</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sigari</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Casalini</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Bedodi</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Conti</LastName><ForeName>A R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Caraceni</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bombardieri</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Surg Oncol</MedlineTA><NlmUniqueID>8504356</NlmUniqueID><ISSNLinking>0748-7983</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>7440-26-8</RegistryNumber><NameOfSubstance UI="D013667">Technetium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001365" MajorTopicYN="N">Axilla</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061305" MajorTopicYN="N">Lymphoscintigraphy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059351" MajorTopicYN="N">Organ Sparing Treatments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013667" MajorTopicYN="N">Technetium</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Axillary reverse mapping</Keyword><Keyword MajorTopicYN="N">Breast cancer</Keyword><Keyword MajorTopicYN="N">Prevention of lymphoedema</Keyword><Keyword MajorTopicYN="N">Selective axillary dissection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>05</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>09</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>09</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24113621</ArticleId><ArticleId IdType="pii">S0748-7983(13)00836-6</ArticleId><ArticleId IdType="doi">10.1016/j.ejso.2013.09.022</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Italie</li></country><region><li>Lombardie</li></region><settlement><li>Milan</li></settlement></list><tree><noCountry><name sortKey="Bedodi, L" sort="Bedodi, L" uniqKey="Bedodi L" first="L" last="Bedodi">L. Bedodi</name><name sortKey="Bombardieri, E" sort="Bombardieri, E" uniqKey="Bombardieri E" first="E" last="Bombardieri">E. Bombardieri</name><name sortKey="Caraceni, A" sort="Caraceni, A" uniqKey="Caraceni A" first="A" last="Caraceni">A. Caraceni</name><name sortKey="Casalini, P" sort="Casalini, P" uniqKey="Casalini P" first="P" last="Casalini">P. Casalini</name><name sortKey="Conti, A R" sort="Conti, A R" uniqKey="Conti A" first="A R" last="Conti">A R Conti</name><name sortKey="Maccauro, M" sort="Maccauro, M" uniqKey="Maccauro M" first="M" last="Maccauro">M. Maccauro</name><name sortKey="Sigari, C" sort="Sigari, C" uniqKey="Sigari C" first="C" last="Sigari">C. Sigari</name></noCountry><country name="Italie"><region name="Lombardie"><name sortKey="Gennaro, M" sort="Gennaro, M" uniqKey="Gennaro M" first="M" last="Gennaro">M. Gennaro</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001892 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001892 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:24113621
|texte= Selective axillary dissection after axillary reverse mapping to prevent breast-cancer-related lymphoedema.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:24113621" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |